Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 May 2018

Xie F, Li P, Gong J, Tan H, Ma J

Abstract excerpt

BACKGROUND: KRAS mutations are prevalent in non-small cell lung cancer (NSCLC) but its clinical implications remain to be determined. Continual profiling of KRAS mutations in patients is challenging, and the study aims to determine the potential use of urinary DNA in disease predictions. METHODS: A total of 150 patients were recruited. To ascertain the clinical relevance of urinary DNA, matched tumor profiles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 28956302
DOI: 10.1007/s12094-017-1754-7

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.PMID 28956302Read ↗

Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.Semantic proximity Read ↗

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.Semantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.Semantic proximity Read ↗

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Semantic proximity Read ↗

TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.